Free Trial
NASDAQ:XDNA

Kelly CRISPR & Gene Editing Technology ETF (XDNA) Price, Holdings, & News

Kelly CRISPR & Gene Editing Technology ETF logo
$7.38
0.00 (0.00%)
(As of 11/1/2024 ET)

About Kelly CRISPR & Gene Editing Technology ETF (NASDAQ:XDNA)

Key Stats

Today's Range
$7.38
$7.38
50-Day Range
$7.38
$7.38
52-Week Range
$5.87
$11.83
Volume
N/A
Average Volume
3,034 shs
Market Capitalization
$2.21 million
Assets Under Management
$2.58 million
Dividend Yield
0.12%
Net Expense Ratio
0.78%
Aggregate Rating
Moderate Buy

ETF Overview

The Strategic CRISPR & Gene Editing Technology ETF (XDNA) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market-cap-weighted index of companies in developed markets that focus on the advancements in DNA modification technology. XDNA was launched on Jan 12, 2022 and is managed by Kelly.

Kelly CRISPR & Gene Editing Technology ETF Expenses

TypeXDNATheme ETFsEquity ETFsNASDAQ ETFsAll ETFs
Management Fee0.78%0.57%0.55%0.49%0.52%
Other Expenses0.00%0.57%0.49%0.41%0.53%
Total Expense0.78%0.73%0.71%0.63%0.71%
Fee Waiver0.00%-0.74%-0.52%-0.32%-0.57%
Net Expense0.78%0.59%0.61%0.56%0.59%
Receive XDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kelly CRISPR & Gene Editing Technology ETF and its competitors with MarketBeat's FREE daily newsletter.

XDNA ETF News Headlines

K-12 Genome Editing at Only $2 a Pop
True paradigm shift
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

XDNA ETF - Frequently Asked Questions

Kelly CRISPR & Gene Editing Technology ETF's stock was trading at $7.38 at the beginning of 2024. Since then, XDNA stock has increased by 0.0% and is now trading at $7.38.
View the best growth stocks for 2024 here
.

Shares of XDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kelly CRISPR & Gene Editing Technology ETF investors own include Meta Platforms (META), RTX (RTX), Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Cloudflare (NET), Birkenstock (BIRK) and Baidu (BIDU).

Fund Details

Issuer
Kelly Strategic Management
Fund Name
Kelly CRISPR & Gene Editing Technology ETF
Tax Classification
Regulated Investment Company
Current Symbol
NASDAQ:XDNA
Inception Date
1/12/2022
Fund Manager
Dustin Lewellyn, Ernesto Tong, Anand Desai
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
Strategic CRISPR & Gene Editing Technology Index
Category
Strategy
Focus
Theme
Development Level
Developed Markets
Region
Global
Number of Holdings
2

Fund Statistics

Assets Under Management
$2.58 million
Average Daily Volume
$0.00
Discount/Premium
0.00%

Administrator, Advisor and Custodian

Administrator
U.S. Bancorp Fund Services, LLC
Advisor
Kelly Strategic Management, LLC
Custodian
U.S. Bank, N.A.
Distributor
Foreside Fund Services, LLC
Transfer Agent
U.S. Bancorp Fund Services, LLC
Trustee
N/A
Lead Market Maker
Jane Street

Miscellaneous

Beta
0.92
Creation Unit
25,000
Creation Fee
$250.00
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Top 10 XDNA Holdings


This page (NASDAQ:XDNA) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners